DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • May 28th, 2020 • Gene Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
THIS DISTRIBUTION AND LICENSE AGREEMENT (“Agreement”) dated as of April 10, 2020, is entered into between Angionetics Inc., a Delaware corporation having its principal place of business at 11568 Sorrento Valley Rd., Suite 14, San Diego, CA 92121 (“Angionetics”), a wholly-owned subsidiary of Gene Biotherapeutics, Inc., and Shanxi Taxus Pharmaceuticals Co., Ltd. (“Licensee”).
REAFFIRMATION AND RATIFICATION AGREEMENTReaffirmation and Ratification Agreement • May 28th, 2020 • Gene Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
Shanxi Taxus Pharmaceuticals Co., Ltd. (“Shanxi”) executed and delivered to Gene Biotherapeutics, Inc. (“Company”) a Restructuring Plan Settlement Letter dated December 19, 2019 (“Letter Agreement”) pursuant to which Shanxi agreed to cancel its $600,000 equity subscription with respect to the Company and treat the payment as an upfront license fee on the Excellagen and Generx licenses described in the Letter Agreement.
FIRST AMENDMENT TO DISTRIBUTION AND LICENSE AGREEMENTDistribution and License Agreement • May 28th, 2020 • Gene Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
The undersigned, Angionetics Inc., a Delaware corporation (“Angionetics”) and a wholly-owned subsidiary of Gene Biotherapeutics, Inc., and Shanxi Taxus Pharmaceuticals Co., Ltd., a China-based company (“Licensee”), desire to amend, as of April 14, 2020, the Distribution and License Agreement, dated as of April 10, 2020 (the “D&L Agreement”). Capitalized terms used but not otherwise defined herein shall have the respective meanings set forth in the D&L Agreement.
PREFERRED STOCK PURCHASE AGREEMENTPreferred Stock Purchase Agreement • May 28th, 2020 • Gene Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Preferred Stock Purchase Agreement (this “Agreement”) is made as of May 22, 2020, by and among Gene Biotherapeutics, Inc. a Delaware corporation with its principal office at 11230 Sorrento Valley Road Suite #220, San Diego, CA 92122 (“CRXM” or the “Company”) and Nostrum Pharmaceuticals, LLC Delaware limited liability company with its principal office at 1370 Hamilton Street Somerset NJ, 08873 (“NPLLC” or the “Purchaser”).
LICENSE AND PATENT ASSIGNMENT AGREEMENTLicense and Patent Assignment Agreement • May 28th, 2020 • Gene Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This LICENSE AND PATENT ASSIGNMENT AGREEMENT (this “Agreement”) dated as of April 10, 2020 is made by Activation Therapeutics Inc., a Delaware corporation (“Activation”), on its own behalf and on behalf of its Affiliates and Shanxi Taxus Pharmaceuticals Co., Ltd., a company incorporated under the laws of the People’s Republic of China (“Shanxi”), with respect to the following facts:
